Instructions For Use
AVE001

Avéli^® is indicated for long-term reduction in the appearance of cellulite in the buttocks and thigh areas of adult females as supported by clinical data demonstrating treatment benefits through one year of observation. Avéli is also indicated for soft tissue dissection during general and plastic surgical procedures. The most common side effects reported were mild pain within the first 24 hours and bruising and tenderness to the touch which typically resolved within 30 days. Some patients returned to normal activities within one day of the procedure and most within a week. As with any medical procedure, there are risks associated with the procedure. Consult with your provider for full safety information. ALWAYS FOLLOW THE DIRECTIONS FOR USE.

References:

Stevens WG, Green JB, Layt C, et al. Multicenter Pivotal Study Demonstrates Safety and Efficacy of a New Cellulite Procedure: Final Results at 12 Months [published online ahead of print, 2022 Nov 10]. Aesthet Surg J. 2022;sjac291
Emanuele E. Cellulite: advances in treatment: facts and controversies. Clin Dermatol. 2013;31(6):725-30.
Stevens WG, Kaminer MS, Fabi SG, Fan L. Study of a New Controlled Focal Septa Release Cellulite Reduction Method. Aesthet Surg J. 2022;42(8):937-945.
Stevens WG, Green JB, Layt C, et al. Multicenter Pivotal Study Demonstrates Safety and Efficacy of a New Cellulite Procedure: 3-Month Results [published online ahead of print, 2022 Jul 5]. Aesthet Surg J. 2022 Jul 5;sjac179. doi:10.1093/asj/sjac179.

About Avéli^®
Find a Provider
Company
Careers

Revelle Aesthetics
Privacy Policy
Site Terms
Instructions For Use AVE001
Instructions For Use AVE002
Patents

Instructions For UseAVE001

Instructions For Use
AVE001